Table 2.

Table summarising the subtractive proteomics strategy and its outcomes. The sixty-nine core proteins were screened through four stages to pinpoint therapeutic targets with highly desirable features. Four proteins namely; I7L, Top1B, VETFS, and A20R were identified as highly druggable, globular, non-host homologous, enzymatic proteins and were subjected to virtual screening in this study. Eight proteins namely, A19R, PAPL, Rpo30, E10R, G1L, Rpo22, E1R and Rpo35 passed the first three stages of screening and remain under investigation for druggability assessment. Proteins that fit under a particular group of are shaded in blue